Literature DB >> 23391599

Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol.

Roman Prymula1, Ahsan Habib, Nancy François, Dorota Borys, Lode Schuerman.   

Abstract

BACKGROUND: Prophylactic paracetamol (PP) was previously shown to reduce primary and booster antibody responses against the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). This study further evaluated the effect of PP on antibody persistence, immunological memory and nasopharyngeal carriage (NPC).
METHODS: Two hundred and twenty children previously primed (3 doses, NCT00370318) and boosted (NCT00496015) with PHiD-CV with (PP group) or without (NPP group) prophylactic paracetamol administration received one PHiD-CV dose in their fourth year of life to assess the induction of immunological memory following previous immunisations. A control group of age-matched unprimed children enrolled in study NCT00496015 received an investigational tetravalent Neisseria meningitidis serogroups A, C, W-135, Y tetanus toxoid-conjugate vaccine, and thus remained unprimed for pneumococcal vaccination. Of these, 223 unprimed children received in the present study at least one PHiD-CV dose of a 2-dose catch-up regimen, which was relevant as control for assessment of immunological memory in PHiD-CV primed children.
RESULTS: Induction of immunological memory was shown irrespective of PP administration at primary and booster vaccination. Antibody geometric mean concentrations were lower in the PP group for serotypes 1, 4, 7F and 9V. Opsonophagocytic titres did not differ significantly between PP and NPP groups. Previous use of PP seemed to have only a minor impact on kinetics of antibody persistence. Reduced NPC of vaccine pneumococcal serotypes and trends towards increased NPC of non-vaccine and non-cross-reactive serotypes were seen in primed groups versus the control group, with no obvious differences between PP and NPP groups.
CONCLUSION: Regardless of whether previous PHiD-CV vaccination was given with or without PP, induction of immunological memory and persistence of PHiD-CV's impact on carriage was seen until at least 28 months post-booster vaccination. Our study results therefore suggest that the lower immune responses after primary and booster vaccination with PP are of transient nature.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23391599     DOI: 10.1016/j.vaccine.2013.01.044

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

Review 1.  Effect of antipyretic analgesics on immune responses to vaccination.

Authors:  Ezzeldin Saleh; M Anthony Moody; Emmanuel B Walter
Journal:  Hum Vaccin Immunother       Date:  2016-05-31       Impact factor: 3.452

2.  A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I).

Authors:  Roman Prymula; Susanna Esposito; Gian Vincenzo Zuccotti; Fang Xie; Daniela Toneatto; Igor Kohl; Peter M Dull
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.

Authors:  Thomas C Mitchell; Carolyn R Casella
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

4.  Absence of an important vaccine and diagnostic target in carriage- and disease-related nontypeable Haemophilus influenzae.

Authors:  Heidi C Smith-Vaughan; Anne B Chang; Derek S Sarovich; Robyn L Marsh; Keith Grimwood; Amanda J Leach; Peter S Morris; Erin P Price
Journal:  Clin Vaccine Immunol       Date:  2013-11-27

5.  Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.

Authors:  David Bin-Chia Wu; Craig Roberts; Vivian Wing Yan Lee; Li-Wen Hong; Kah Kee Tan; Vivienne Mak; Kenneth Kwing Chin Lee
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

Review 6.  10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children.

Authors:  Greg L Plosker
Journal:  Paediatr Drugs       Date:  2014-10       Impact factor: 3.022

7.  10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) induces memory B cell responses in healthy Kenyan toddlers.

Authors:  D M Muema; E W Nduati; M Uyoga; M Bashraheil; J A G Scott; L L Hammitt; B C Urban
Journal:  Clin Exp Immunol       Date:  2015-06-10       Impact factor: 4.330

8.  Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial.

Authors:  Kerry-Ann F O'Grady; Keith Grimwood; Allan Cripps; Edward K Mulholland; Peter Morris; Paul J Torzillo; Nicholas Wood; Heidi Smith-Vaughan; Amber Revell; Andrew Wilson; Peter Van Asperen; Peter Richmond; Ruth Thornton; Sheree Rablin; Anne B Chang
Journal:  Trials       Date:  2013-09-05       Impact factor: 2.279

9.  Trends in the epidemiology of invasive Haemophilus influenzae disease in Queensland, Australia from 2000 to 2013: what is the impact of an increase in invasive non-typable H. influenzae (NTHi)?

Authors:  J Wan Sai Cheong; H Smith; C Heney; J Robson; S Schlebusch; J Fu; C Nourse
Journal:  Epidemiol Infect       Date:  2015-03-12       Impact factor: 4.434

10.  Optimising assessments of the epidemiological impact in The Netherlands of paediatric immunisation with 13-valent pneumococcal conjugate vaccine using dynamic transmission modelling.

Authors:  Elisabetta De Cao; Alessia Melegaro; Rogier Klok; Maarten Postma
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.